MedPath

PET scan for measuring response in lymphoma of brai

Not Applicable
Conditions
Health Condition 1: C859- Non-Hodgkin lymphoma, unspecified
Registration Number
CTRI/2021/05/033776
Lead Sponsor
Tata Memorial Centre Mumbai
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Diagnosed cases of PCNSL

2.Receiving high dose methotrexate based induction therapy

3.Patient available for response assessment MRI & PET-CT Brain post induction chemotherapy

4.Patient able to understand & sign the consent.

Exclusion Criteria

1.Patients who cannot complete the high dose methotrexate based induction chemotherapy due to toxicity or other reasons except progression .

2.Patient with any contrast allergies or hypersensitivities.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Sensitivity and specificity of PET-CT as compared to MRI (gold standard for response assessment)Timepoint: 2,4 and 6 months
Secondary Outcome Measures
NameTimeMethod
Prognostic value of MTV and TLGTimepoint: At start that time point 0;Prognostic value of PET responseTimepoint: 2, 4 and 6 months;Utility of PET-MRI fusionTimepoint: 2,4 and 6 months
© Copyright 2025. All Rights Reserved by MedPath